ALXN - Alexion Pharmaceuticals, Inc.
111.74 0.00 (0.00%)
After hours: 4:12PM EDT
| Previous Close | 112.96 |
| Open | 112.40 |
| Bid | 111.72 x 100 |
| Ask | 114.12 x 100 |
| Day's Range | 111.30 - 113.27 |
| 52 Week Range | 96.18 - 149.34 |
| Volume | 900,167 |
| Avg. Volume | 2,129,159 |
| Market Cap | 24.846B |
| Beta | 1.07 |
| PE Ratio (TTM) | 56.72 |
| EPS (TTM) | 1.97 |
| Earnings Date | Apr 26, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 158.60 |
- Zacks•yesterday
Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics
The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.
- Zacks•6 days ago
Pharma M&A Active This Week: 4 Potential Buyout Targets
Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.
- Market Realist•6 days ago
Alexion: Analysts Raise Their Target Prices
Alexion Pharmaceuticals (ALXN) is one of the leading biotechnology firms. Soliris is approved to treat aHUS (atypical hemolytic uremic syndrome) and PHN (paroxysmal nocturnal hemoglobinuria). Alexion’s latest acquisition of Wilson Therapeutics is a turnaround strategy that’s being implemented to restructure Alexion’s performance and investors’ sentiments in the market.
Market Realist•6 days agoWTX101: A Superior Treatment for Wilson Disease
On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced the acquisition of Wilson Therapeutics, which is developing a “first-of-its-kind” treatment for Wilson disease. Currently, Wilson disease is treated with copper chelators, Penicillamine or Trientine, to remove copper from serum. The drug has the potential to become the standard of care for Wilson disease patients.
Market Realist•6 days agoWilson Disease: A Market Opportunity for Alexion
On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced the acquisition of Wilson Therapeutics. Wilson Therapeutics is developing a drug to treat Wilson disease. Wilson disease is a rare genetic disorder that’s potentially life-threatening.
Market Realist•6 days agoStrategic Rationale behind Alexion’s Acquisition
Wilson Therapeutics is a biopharmaceutical company focused on developing rare disease therapies. The company is listed on the Nasdaq Stockholm Exchange and has a market capitalization of 6.5 billion Swedish kronor. Wilson Therapeutics is developing a novel therapy to treat Wilson disease, which is a rare genetic and chronic disorder characterized by an accumulation of copper in the brain, liver, and other vital organs.
Market Realist•6 days agoAlexion to Acquire Wilson Therapeutics for $855 Million
On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders to acquire all of the company’s outstanding shares. Wilson Therapeutics is a Sweden-based biopharmaceuticals firm. The acquisition will advance Alexion’s long-term growth strategy, which consists of advancing and rebuilding its rare disease pipeline. Alexion aims to accelerate the diversification of its product portfolio.
- ACCESSWIRE•6 days ago
Blog Exposure - Alexion Pharma to Acquire Swedish Biotech Wilson Therapeutics
Stock Monitor: Argos Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free research report on Alexion Pharma, Inc. (NASDAQ: ALXN ...
- Zacks•7 days ago
Alexion (ALXN) to Acquire Wilson Therapeutics for $855M
Alexion (ALXN) announces that the company will acquire Sweden-based Wilson Therapeutics for $855 million, the latest company to join the ongoing acquisitions spree in the biotech sector.
- Business Wire•7 days ago
Alexion to Report First Quarter 2018 Results on Thursday, April 26, 2018
Alexion Pharmaceuticals, Inc. today announced that the Company will report its financial results for the first quarter ended March 31, 2018 on Thursday, April 26, 2018 before the US financial markets open.
- Investor's Business Daily•8 days ago
How Alexion Could Diversify From Its Cash Cow To Battle Valeant, Teva
Alexion Pharmaceuticals will snap up Wilson Therapeutics in a move that helps it diversify from its blockbuster franchise and compete with Valeant and Teva.
Market Realist•8 days agoJakafi Continues to Be Strong Growth Driver for Incyte in 2018
Incyte has projected Jakafi’s GAAP (generally accepted accounting principles) and non-GAAP revenues for full-year 2018 to fall in the range of $1.35 billion to $1.4 billion. This revenue performance could be driven by an anticipated rise in demand for the drug in existing rare blood cancer indications of myelofibrosis (or MF) and polycythemia vera (or PV) as well as from potential new indications such as graft versus host disease (or GVHD) and essential-thrombocythemia (or ET). Jakafi has been granted orphan drug designation in MF, PV, ET, GVHD, and acute lymphoblastic leukemia (ALL) indications.
- Barrons.com•8 days ago
Vertex Is Worth More Than You Think
Shares of Vertex Pharmaceuticals (VRTX) have easily outrun the market year-to-date, rising 8%, and the drug maker has notched returns of more than 42% in the past year. Analyst Hartaj Singh reiterated an Outperform rating and $190 price target on the shares Wednesday, but notes that Vertex could see as much as 50% upside to that target, which would put the shares at $285.
- Reuters•8 days ago
Biotech M&A rolls on as Alexion snaps up Wilson for $855 mln
Alexion Pharmaceuticals has agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million), boosting its line-up of rare disease drugs as a wave of deal-making in the biotechnology sector continues. Alexion was one of the stars of the biotech sector in the first half of this decade, but it has stumbled more recently following an exodus of top management and a sales practices scandal related to Soliris, its pricey rare disease treatment.
- Simply Wall St.•8 days ago
Why Alexion Pharmaceuticals Inc (NASDAQ:ALXN) May Not Be As Efficient As Its Industry
Alexion Pharmaceuticals Inc (NASDAQ:ALXN) generated a below-average return on equity of 4.98% in the past 12 months, while its industry returned 17.87%. An investor may attribute an inferior ROE toRead More...
- Reuters•9 days ago
Alexion to buy Swedish biotech Wilson Therapeutics for $855 mln
Alexion Pharmaceuticals said on Wednesday it had agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns to boost its line-up of rare disease drugs. The U.S. group is acquiring the business ...
- The Wall Street Journal•9 days ago
[$$] Alexion Makes Bid for Sweden's Wilson Therapeutics
Alexion Pharmaceuticals has made a $788 million bid for Swedish biopharmaceutical company Wilson Therapeutics as it looks to bolster its portfolio of treatments for rare disorders.
- Business Wire•9 days ago
Alexion to Acquire Wilson Therapeutics
Alexion Pharmaceuticals, Inc. and Wilson Therapeutics AB announced today that Alexion has made a recommended public cash offer to the shareholders in Wilson Therapeutics to acquire all outstanding shares in Wilson Therapeutics by way of a tender offer, through a wholly-owned subsidiary.
- InvestorPlace•9 days ago
4 Biotech Stocks With Leaky Pipelines
When it comes to biotech stocks, a pipeline can make or break a company. Due to the nature of the clinical trial system, a company can work for years on a new drug only to have all that work disappear when a therapy is found unsafe and ineffective. After a given amount of time, any company can produce a generic version of the drug a biotech company spent millions developing and have come to depend on revenue-wise.
- Thomson Reuters StreetEvents•9 days ago
Edited Transcript of ALXN presentation 7-Mar-17 6:05pm GMT
Alexion Pharmaceuticals Inc at Raymond James Institutional Investors Conference
Markit•9 days agoSee what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting ALXN. Over the last one-month, outflows of investor capital in ETFs holding ALXN totaled $14.43 billion.
- InvestorPlace•10 days ago
Alexion Pharmaceuticals, Inc. Is Researching a Turnaround
Today, biotech takes us to the next level of healthcare by drawing on the traditional biological sciences and adding new capabilities from genetics, embryology, chemical engineering, bioprocess engineering, information technology and even robotics. There have been many disappointments along with the successes through the years, and I’ve avoided many biotech stocks as a result. The company specializes in the development of orphan drugs, treating patients with severe and life-threatening rare diseases.
Market Realist•16 days agoBioMarin Pharmaceutical’s Drugs in 4Q17 and Fiscal 2017
A Post-4Q17 Update on BioMarin Pharmaceuticals
- ACCESSWIRE•17 days ago
Today’s Research Reports on Trending Tickers: Centene and Alexion Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / April 2, 2018 / U.S. markets closed in the green Thursday, with major indexes all rising more than 1 percent. Most sectors participated in the broad rally and saw some strong ...
- Motley Fool•22 days ago
When Will They Learn? 4 Huge Biotech Blowups
AbbVie isn't the first big drugmaker to pay billions for a dud. Here's what you can learn from their mistakes.
